Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 35 entries
Sorted by: Best Match Show Resources per page
Microbiota Modulation With Synbiotic Decreases Liver Fibrosis in a High Fat Choline Deficient Diet Mice Model of Non-Alcoholic Steatohepatitis (NASH).

GE Portuguese journal of gastroenterology

Cortez-Pinto H, Borralho P, Machado J, Lopes MT, Gato IV, Santos AM, Guerreiro AS.
PMID: 28868449
GE Port J Gastroenterol. 2016 Mar 31;23(3):132-141. doi: 10.1016/j.jpge.2016.01.004. eCollection 2016.

BACKGROUND: Gut microbiota may play a role in non-alcoholic steatohepatitis (NASH). Previous studies showed that prebiotics and probiotics might halt the progression of steatohepatitis.AIM: To clarify the potential effect of Synbiotic 2000METHODS: Twenty-seven C57BL/6 mice were divided into three...

Cite
Cortez-Pinto H, Borralho P, Machado J, et al. Microbiota Modulation With Synbiotic Decreases Liver Fibrosis in a High Fat Choline Deficient Diet Mice Model of Non-Alcoholic Steatohepatitis (NASH). GE Port J Gastroenterol. 2016;23(3):132-141doi: 10.1016/j.jpge.2016.01.004.
Cortez-Pinto, H., Borralho, P., Machado, J., Lopes, M. T., Gato, I. V., Santos, A. M., & Guerreiro, A. S. (2016). Microbiota Modulation With Synbiotic Decreases Liver Fibrosis in a High Fat Choline Deficient Diet Mice Model of Non-Alcoholic Steatohepatitis (NASH). GE Portuguese journal of gastroenterology, 23(3), 132-141. https://doi.org/10.1016/j.jpge.2016.01.004
Cortez-Pinto, Helena, et al. "Microbiota Modulation With Synbiotic Decreases Liver Fibrosis in a High Fat Choline Deficient Diet Mice Model of Non-Alcoholic Steatohepatitis (NASH)." GE Portuguese journal of gastroenterology vol. 23,3 (2016): 132-141. doi: https://doi.org/10.1016/j.jpge.2016.01.004
Cortez-Pinto H, Borralho P, Machado J, Lopes MT, Gato IV, Santos AM, Guerreiro AS. Microbiota Modulation With Synbiotic Decreases Liver Fibrosis in a High Fat Choline Deficient Diet Mice Model of Non-Alcoholic Steatohepatitis (NASH). GE Port J Gastroenterol. 2016 Mar 31;23(3):132-141. doi: 10.1016/j.jpge.2016.01.004. eCollection 2016. PMID: 28868449; PMCID: PMC5580012.
Copy Download .nbib Format: NLM
Publisher Correction: Alcoholic liver disease.

Nature reviews. Disease primers

Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H.
PMID: 30154473
Nat Rev Dis Primers. 2018 Aug 28;4(1):18. doi: 10.1038/s41572-018-0021-8.

The originally published article contained an error in figure 8 part a, in which cut off values for F3 fibrosis, cirrhosis, and screening for oesophageal varices and HCC were incorrectly presented as 20 kPa for screening for oesophageal varices...

Cite
Seitz HK, Bataller R, Cortez-Pinto H, et al. Publisher Correction: Alcoholic liver disease. Nat Rev Dis Primers. 2018;4(1):18doi: 10.1038/s41572-018-0021-8.
Seitz, H. K., Bataller, R., Cortez-Pinto, H., Gao, B., Gual, A., Lackner, C., Mathurin, P., Mueller, S., Szabo, G., & Tsukamoto, H. (2018). Publisher Correction: Alcoholic liver disease. Nature reviews. Disease primers, 4(1), 18. https://doi.org/10.1038/s41572-018-0021-8
Seitz, Helmut K, et al. "Publisher Correction: Alcoholic liver disease." Nature reviews. Disease primers vol. 4,1 (2018): 18. doi: https://doi.org/10.1038/s41572-018-0021-8
Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H. Publisher Correction: Alcoholic liver disease. Nat Rev Dis Primers. 2018 Aug 28;4(1):18. doi: 10.1038/s41572-018-0021-8. PMID: 30154473.
Copy Download .nbib Format: NLM
Prevalence, risk factors and global impact of musculoskeletal injuries among endoscopists: a nationwide European study.

Endoscopy international open

Morais R, Vilas-Boas F, Pereira P, Lopes P, Simões C, Dantas E, Cunha I, Roseira J, Cortez-Pinto J, Silva J, Lage J, Caine M, Rocha M, Flor de Lima M, Costa Santos MP, Garrido M, Sousa P, Marcos P, Azevedo R, Castro R, Cúrdia Gonçalves T, Leal T, Magno-Pereira V, Ramalho R, Rodrigues-Pinto E, Macedo G.
PMID: 32258368
Endosc Int Open. 2020 Apr;8(4):E470-E480. doi: 10.1055/a-1038-4343. Epub 2020 Mar 23.

No abstract available.

Cite
Morais R, Vilas-Boas F, Pereira P, et al. Prevalence, risk factors and global impact of musculoskeletal injuries among endoscopists: a nationwide European study. Endosc Int Open. 2020;8(4):E470-E480doi: 10.1055/a-1038-4343.
Morais, R., Vilas-Boas, F., Pereira, P., Lopes, P., Simões, C., Dantas, E., Cunha, I., Roseira, J., Cortez-Pinto, J., Silva, J., Lage, J., Caine, M., Rocha, M., Flor de Lima, M., Costa Santos, M. P., Garrido, M., Sousa, P., Marcos, P., Azevedo, R., Castro, R., Cúrdia Gonçalves, T., Leal, T., Magno-Pereira, V., Ramalho, R., Rodrigues-Pinto, E., & Macedo, G. (2020). Prevalence, risk factors and global impact of musculoskeletal injuries among endoscopists: a nationwide European study. Endoscopy international open, 8(4), E470-E480. https://doi.org/10.1055/a-1038-4343
Morais, Rui, et al. "Prevalence, risk factors and global impact of musculoskeletal injuries among endoscopists: a nationwide European study." Endoscopy international open vol. 8,4 (2020): E470-E480. doi: https://doi.org/10.1055/a-1038-4343
Morais R, Vilas-Boas F, Pereira P, Lopes P, Simões C, Dantas E, Cunha I, Roseira J, Cortez-Pinto J, Silva J, Lage J, Caine M, Rocha M, Flor de Lima M, Costa Santos MP, Garrido M, Sousa P, Marcos P, Azevedo R, Castro R, Cúrdia Gonçalves T, Leal T, Magno-Pereira V, Ramalho R, Rodrigues-Pinto E, Macedo G. Prevalence, risk factors and global impact of musculoskeletal injuries among endoscopists: a nationwide European study. Endosc Int Open. 2020 Apr;8(4):E470-E480. doi: 10.1055/a-1038-4343. Epub 2020 Mar 23. PMID: 32258368; PMCID: PMC7089795.
Copy Download .nbib Format: NLM
The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.

Lancet (London, England)

Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP.
PMID: 34863359
Lancet. 2022 Jan 01;399(10319):61-116. doi: 10.1016/S0140-6736(21)01701-3. Epub 2021 Dec 02.

No abstract available.

Cite
Karlsen TH, Sheron N, Zelber-Sagi S, et al. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet. 2021;399(10319):61-116doi: 10.1016/S0140-6736(21)01701-3.
Karlsen, T. H., Sheron, N., Zelber-Sagi, S., Carrieri, P., Dusheiko, G., Bugianesi, E., Pryke, R., Hutchinson, S. J., Sangro, B., Martin, N. K., Cecchini, M., Dirac, M. A., Belloni, A., Serra-Burriel, M., Ponsioen, C. Y., Sheena, B., Lerouge, A., Devaux, M., Scott, N., Hellard, M., Verkade, H. J., Sturm, E., Marchesini, G., Yki-Järvinen, H., Byrne, C. D., Targher, G., Tur-Sinai, A., Barrett, D., Ninburg, M., Reic, T., Taylor, A., Rhodes, T., Treloar, C., Petersen, C., Schramm, C., Flisiak, R., Simonova, M. Y., Pares, A., Johnson, P., Cucchetti, A., Graupera, I., Lionis, C., Pose, E., Fabrellas, N., Ma, A. T., Mendive, J. M., Mazzaferro, V., Rutter, H., Cortez-Pinto, H., Kelly, D., Burton, R., Lazarus, J. V., Ginès, P., Buti, M., Newsome, P. N., Burra, P., & Manns, M. P. (2022). The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet (London, England), 399(10319), 61-116. https://doi.org/10.1016/S0140-6736(21)01701-3
Karlsen, Tom H, et al. "The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality." Lancet (London, England) vol. 399,10319 (2022): 61-116. doi: https://doi.org/10.1016/S0140-6736(21)01701-3
Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet. 2022 Jan 01;399(10319):61-116. doi: 10.1016/S0140-6736(21)01701-3. Epub 2021 Dec 02. PMID: 34863359.
Copy Download .nbib Format: NLM
Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease.

Journal of hepatology

Lackner C, Stauber RE, Davies S, Denk H, Dienes HP, Gnemmi V, Guido M, Miquel R, Paradis V, Schirmacher P, Terracciano L, Berghold A, Pregartner G, Binder L, Douschan P, Rainer F, Sygulla S, Jager M, Rautou PE, Bumbu A, Horhat A, Rusu I, Stefanescu H, Detlefsen S, Krag A, Thiele M, Cortez-Pinto H, Moreno C, Gouw ASH, Tiniakos DG.
PMID: 34126105
J Hepatol. 2021 Oct;75(4):810-819. doi: 10.1016/j.jhep.2021.05.029. Epub 2021 Jun 11.

BACKGROUND & AIMS: The SALVE Histopathology Group (SHG) developed and validated a grading and staging system for the clinical and full histological spectrum of alcohol-related liver disease (ALD) and evaluated its prognostic utility in a multinational cohort of 445...

Cite
Lackner C, Stauber RE, Davies S, et al. Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease. J Hepatol. 2021;75(4):810-819doi: 10.1016/j.jhep.2021.05.029.
Lackner, C., Stauber, R. E., Davies, S., Denk, H., Dienes, H. P., Gnemmi, V., Guido, M., Miquel, R., Paradis, V., Schirmacher, P., Terracciano, L., Berghold, A., Pregartner, G., Binder, L., Douschan, P., Rainer, F., Sygulla, S., Jager, M., Rautou, P. E., Bumbu, A., Horhat, A., Rusu, I., Stefanescu, H., Detlefsen, S., Krag, A., Thiele, M., Cortez-Pinto, H., Moreno, C., Gouw, A. S. H., & Tiniakos, D. G. (2021). Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease. Journal of hepatology, 75(4), 810-819. https://doi.org/10.1016/j.jhep.2021.05.029
Lackner, Carolin, et al. "Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease." Journal of hepatology vol. 75,4 (2021): 810-819. doi: https://doi.org/10.1016/j.jhep.2021.05.029
Lackner C, Stauber RE, Davies S, Denk H, Dienes HP, Gnemmi V, Guido M, Miquel R, Paradis V, Schirmacher P, Terracciano L, Berghold A, Pregartner G, Binder L, Douschan P, Rainer F, Sygulla S, Jager M, Rautou PE, Bumbu A, Horhat A, Rusu I, Stefanescu H, Detlefsen S, Krag A, Thiele M, Cortez-Pinto H, Moreno C, Gouw ASH, Tiniakos DG. Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease. J Hepatol. 2021 Oct;75(4):810-819. doi: 10.1016/j.jhep.2021.05.029. Epub 2021 Jun 11. PMID: 34126105.
Copy Download .nbib Format: NLM
Real-Time Optical Diagnosis of Colorectal Polyps in the Routine Clinical Practice Using the NICE and WASP Classifications in a Nonacademic Setting.

GE Portuguese journal of gastroenterology

Castela J, Mão de Ferro S, Rosa I, Lage P, Ferreira S, Pereira Silva J, Cortez Pinto J, Vale Rodrigues R, Moleiro J, Claro I, Esteves S, Dias Pereira A.
PMID: 31559322
GE Port J Gastroenterol. 2019 Aug;26(5):314-323. doi: 10.1159/000495258. Epub 2019 Jan 10.

BACKGROUND: Narrow-band imaging (NBI) allows "in vivo" classification of colorectal polyps.OBJECTIVES: We evaluated the optical diagnosis by nonexpert community-based endoscopists in routine clinical practice, the impact of training, and whether the endoscopists could achieve the threshold for the "do...

Cite
Castela J, Mão de Ferro S, Rosa I, et al. Real-Time Optical Diagnosis of Colorectal Polyps in the Routine Clinical Practice Using the NICE and WASP Classifications in a Nonacademic Setting. GE Port J Gastroenterol. 2019;26(5):314-323doi: 10.1159/000495258.
Castela, J., Mão de Ferro, S., Rosa, I., Lage, P., Ferreira, S., Pereira Silva, J., Cortez Pinto, J., Vale Rodrigues, R., Moleiro, J., Claro, I., Esteves, S., & Dias Pereira, A. (2019). Real-Time Optical Diagnosis of Colorectal Polyps in the Routine Clinical Practice Using the NICE and WASP Classifications in a Nonacademic Setting. GE Portuguese journal of gastroenterology, 26(5), 314-323. https://doi.org/10.1159/000495258
Castela, Joana, et al. "Real-Time Optical Diagnosis of Colorectal Polyps in the Routine Clinical Practice Using the NICE and WASP Classifications in a Nonacademic Setting." GE Portuguese journal of gastroenterology vol. 26,5 (2019): 314-323. doi: https://doi.org/10.1159/000495258
Castela J, Mão de Ferro S, Rosa I, Lage P, Ferreira S, Pereira Silva J, Cortez Pinto J, Vale Rodrigues R, Moleiro J, Claro I, Esteves S, Dias Pereira A. Real-Time Optical Diagnosis of Colorectal Polyps in the Routine Clinical Practice Using the NICE and WASP Classifications in a Nonacademic Setting. GE Port J Gastroenterol. 2019 Aug;26(5):314-323. doi: 10.1159/000495258. Epub 2019 Jan 10. PMID: 31559322; PMCID: PMC6751415.
Copy Download .nbib Format: NLM
Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib.

European journal of gastroenterology & hepatology

Reis D, Moura M, Freitas LC, Carvalhana S, Nogueira PJ, Gaio R, Marinho RT, Cortez-Pinto H.
PMID: 33177383
Eur J Gastroenterol Hepatol. 2020 Nov 10; doi: 10.1097/MEG.0000000000001974. Epub 2020 Nov 10.

BACKGROUND AND AIMS: Sorafenib, used for advanced-stage hepatocellular carcinoma (HCC), has an overall survival (OS) of 10 months. However, some patients have better response and long-term survival (LTS). Aims to assess predictive factors for LTS.METHODS: Retrospectively reviewed 77 advanced...

Cite
Reis D, Moura M, Freitas LC, et al. Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol. 2020;doi: 10.1097/MEG.0000000000001974.
Reis, D., Moura, M., Freitas, L. C., Carvalhana, S., Nogueira, P. J., Gaio, R., Marinho, R. T., & Cortez-Pinto, H. (2020). Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib. European journal of gastroenterology & hepatology, . https://doi.org/10.1097/MEG.0000000000001974
Reis, Daniela, et al. "Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib." European journal of gastroenterology & hepatology vol. (2020). doi: https://doi.org/10.1097/MEG.0000000000001974
Reis D, Moura M, Freitas LC, Carvalhana S, Nogueira PJ, Gaio R, Marinho RT, Cortez-Pinto H. Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol. 2020 Nov 10; doi: 10.1097/MEG.0000000000001974. Epub 2020 Nov 10. PMID: 33177383.
Copy Download .nbib Format: NLM
The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.

Lancet (London, England)

Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP.
PMID: 34863359
Lancet. 2021 Dec 01; doi: 10.1016/S0140-6736(21)01701-3. Epub 2021 Dec 01.

No abstract available.

Cite
Karlsen TH, Sheron N, Zelber-Sagi S, et al. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet. 2021;doi: 10.1016/S0140-6736(21)01701-3.
Karlsen, T. H., Sheron, N., Zelber-Sagi, S., Carrieri, P., Dusheiko, G., Bugianesi, E., Pryke, R., Hutchinson, S. J., Sangro, B., Martin, N. K., Cecchini, M., Dirac, M. A., Belloni, A., Serra-Burriel, M., Ponsioen, C. Y., Sheena, B., Lerouge, A., Devaux, M., Scott, N., Hellard, M., Verkade, H. J., Sturm, E., Marchesini, G., Yki-Järvinen, H., Byrne, C. D., Targher, G., Tur-Sinai, A., Barrett, D., Ninburg, M., Reic, T., Taylor, A., Rhodes, T., Treloar, C., Petersen, C., Schramm, C., Flisiak, R., Simonova, M. Y., Pares, A., Johnson, P., Cucchetti, A., Graupera, I., Lionis, C., Pose, E., Fabrellas, N., Ma, A. T., Mendive, J. M., Mazzaferro, V., Rutter, H., Cortez-Pinto, H., Kelly, D., Burton, R., Lazarus, J. V., Ginès, P., Buti, M., Newsome, P. N., Burra, P., & Manns, M. P. (2021). The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet (London, England), . https://doi.org/10.1016/S0140-6736(21)01701-3
Karlsen, Tom H, et al. "The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality." Lancet (London, England) vol. (2021). doi: https://doi.org/10.1016/S0140-6736(21)01701-3
Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet. 2021 Dec 01; doi: 10.1016/S0140-6736(21)01701-3. Epub 2021 Dec 01. PMID: 34863359.
Copy Download .nbib Format: NLM
Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity.

World journal of gastrointestinal pharmacology and therapeutics

Telles-Correia D, Barbosa A, Cortez-Pinto H, Campos C, Rocha NB, Machado S.
PMID: 28217372
World J Gastrointest Pharmacol Ther. 2017 Feb 06;8(1):26-38. doi: 10.4292/wjgpt.v8.i1.26.

The liver is the organ by which the majority of substances are metabolized, including psychotropic drugs. There are several pharmacokinetic changes in end-stage liver disease that can interfere with the metabolization of psychotropic drugs. This fact is particularly true...

Cite
Telles-Correia D, Barbosa A, Cortez-Pinto H, et al. Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity. World J Gastrointest Pharmacol Ther. 2017;8(1):26-38doi: 10.4292/wjgpt.v8.i1.26.
Telles-Correia, D., Barbosa, A., Cortez-Pinto, H., Campos, C., Rocha, N. B., & Machado, S. (2017). Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity. World journal of gastrointestinal pharmacology and therapeutics, 8(1), 26-38. https://doi.org/10.4292/wjgpt.v8.i1.26
Telles-Correia, Diogo, et al. "Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity." World journal of gastrointestinal pharmacology and therapeutics vol. 8,1 (2017): 26-38. doi: https://doi.org/10.4292/wjgpt.v8.i1.26
Telles-Correia D, Barbosa A, Cortez-Pinto H, Campos C, Rocha NB, Machado S. Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity. World J Gastrointest Pharmacol Ther. 2017 Feb 06;8(1):26-38. doi: 10.4292/wjgpt.v8.i1.26. PMID: 28217372; PMCID: PMC5292604.
Copy Download .nbib Format: NLM
Fatty liver in lean patients: is it a different disease?.

Annals of gastroenterology

Verdelho Machado M, Cortez-Pinto H.
PMID: 24713794
Ann Gastroenterol. 2012;25(1):1-2.

No abstract available.

Cite
Verdelho Machado M, Cortez-Pinto H. Fatty liver in lean patients: is it a different disease?. Ann Gastroenterol. 2012;25(1):1-2
Verdelho Machado, M., & Cortez-Pinto, H. (2012). Fatty liver in lean patients: is it a different disease?. Annals of gastroenterology, 25(1), 1-2.
Verdelho Machado, Mariana, and Cortez-Pinto, Helena. "Fatty liver in lean patients: is it a different disease?." Annals of gastroenterology vol. 25,1 (2012): 1-2.
Verdelho Machado M, Cortez-Pinto H. Fatty liver in lean patients: is it a different disease?. Ann Gastroenterol. 2012;25(1):1-2. PMID: 24713794; PMCID: PMC3959355.
Copy Download .nbib Format: NLM
Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease.

United European gastroenterology journal

Cortez-Pinto H, Liberal R, Lopes S, Machado MV, Carvalho J, Dias T, Santos A, Agostinho C, Figueiredo P, Loureiro R, Martins A, Alexandrino G, Cotrim I, Leal C, Presa J, Mesquita M, Nunes J, Gouveia C, Vale AHE, Alves AL, Coelho M, Maia L, Pedroto I, Banhudo A, Pinto JS, Gomes MV, Oliveira J, Andreozzi V, Calinas F.
PMID: 34102008
United European Gastroenterol J. 2021 Jul;9(6):699-706. doi: 10.1002/ueg2.12095. Epub 2021 Jun 08.

BACKGROUND: The current standard of treatment in primary biliary cholangitis (PBC) is ursodeoxycholic acid (UDCA), although a considerable proportion of patients show incomplete response resulting in disease progression.OBJECTIVE: This study aimed to assess the prevalence of incomplete response to...

Cite
Cortez-Pinto H, Liberal R, Lopes S, et al. Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease. United European Gastroenterol J. 2021;9(6):699-706doi: 10.1002/ueg2.12095.
Cortez-Pinto, H., Liberal, R., Lopes, S., Machado, M. V., Carvalho, J., Dias, T., Santos, A., Agostinho, C., Figueiredo, P., Loureiro, R., Martins, A., Alexandrino, G., Cotrim, I., Leal, C., Presa, J., Mesquita, M., Nunes, J., Gouveia, C., Vale, A. H. E., Alves, A. L., Coelho, M., Maia, L., Pedroto, I., Banhudo, A., Pinto, J. S., Gomes, M. V., Oliveira, J., Andreozzi, V., & Calinas, F. (2021). Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease. United European gastroenterology journal, 9(6), 699-706. https://doi.org/10.1002/ueg2.12095
Cortez-Pinto, Helena, et al. "Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease." United European gastroenterology journal vol. 9,6 (2021): 699-706. doi: https://doi.org/10.1002/ueg2.12095
Cortez-Pinto H, Liberal R, Lopes S, Machado MV, Carvalho J, Dias T, Santos A, Agostinho C, Figueiredo P, Loureiro R, Martins A, Alexandrino G, Cotrim I, Leal C, Presa J, Mesquita M, Nunes J, Gouveia C, Vale AHE, Alves AL, Coelho M, Maia L, Pedroto I, Banhudo A, Pinto JS, Gomes MV, Oliveira J, Andreozzi V, Calinas F. Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease. United European Gastroenterol J. 2021 Jul;9(6):699-706. doi: 10.1002/ueg2.12095. Epub 2021 Jun 08. PMID: 34102008; PMCID: PMC8280809.
Copy Download .nbib Format: NLM
Distant Thromboembolic Disease Diagnosed by Endoscopic Ultrasound in Pancreatic Cancer: A Case Series.

GE Portuguese journal of gastroenterology

Atalaia-Martins C, Pinto-Marques P, Mocanu I, Cortêz-Pinto J, Serra D.
PMID: 30480049
GE Port J Gastroenterol. 2018 Nov;25(6):317-321. doi: 10.1159/000487151. Epub 2018 Mar 06.

Thrombosis and cancer have a very well-known association. Pancreatic cancer has the highest risk for thrombotic events amongst gastrointestinal cancers and is a leading direct cause of death in cancer patients. We assessed the role of endoscopic ultrasound (EUS)...

Cite
Atalaia-Martins C, Pinto-Marques P, Mocanu I, et al. Distant Thromboembolic Disease Diagnosed by Endoscopic Ultrasound in Pancreatic Cancer: A Case Series. GE Port J Gastroenterol. 2018;25(6):317-321doi: 10.1159/000487151.
Atalaia-Martins, C., Pinto-Marques, P., Mocanu, I., Cortêz-Pinto, J., & Serra, D. (2018). Distant Thromboembolic Disease Diagnosed by Endoscopic Ultrasound in Pancreatic Cancer: A Case Series. GE Portuguese journal of gastroenterology, 25(6), 317-321. https://doi.org/10.1159/000487151
Atalaia-Martins, Catarina, et al. "Distant Thromboembolic Disease Diagnosed by Endoscopic Ultrasound in Pancreatic Cancer: A Case Series." GE Portuguese journal of gastroenterology vol. 25,6 (2018): 317-321. doi: https://doi.org/10.1159/000487151
Atalaia-Martins C, Pinto-Marques P, Mocanu I, Cortêz-Pinto J, Serra D. Distant Thromboembolic Disease Diagnosed by Endoscopic Ultrasound in Pancreatic Cancer: A Case Series. GE Port J Gastroenterol. 2018 Nov;25(6):317-321. doi: 10.1159/000487151. Epub 2018 Mar 06. PMID: 30480049; PMCID: PMC6243960.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 35 entries